Biologic response-modifying agents: What is an appropriate phase I–II strategy?

S. Carter

DOI: https://doi.org/10.1007/BF00206036

1980-08-01

Cancer Immunology and Immunotherapy

Abstract:

What problem does this paper attempt to address?

Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Dariusz Rozkiewicz,Justyna Magdalena Hermanowicz,Iwona Kwiatkowska,Anna Krupa,Dariusz Pawlak

DOI: https://doi.org/10.3390/molecules28052400

IF: 4.6

2023-03-06

Molecules

Abstract:In the last few decades, there has been a growing interest in Bruton's tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and differentiation. Evidence demonstrating the expression of BTK on the majority of hematological cells has led to the hypothesis that BTK inhibitors (BTKIs) such as ibrutinib can be an effective treatment for leukemias and lymphomas. However, a growing body of experimental and clinical data has demonstrated the significance of BTK, not just in B-cell malignancies, but also in solid tumors, such as breast, ovarian, colorectal, and prostate cancers. In addition, enhanced BTK activity is correlated with autoimmune disease. This gave rise to the hypothesis that BTK inhibitors can be beneficial in the therapy of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), Sjögren's syndrome (SS), allergies, and asthma. In this review article, we summarize the most recent findings regarding this kinase as well as the most advanced BTK inhibitors that have been developed to date and their clinical applications mainly in cancer and chronic inflammatory disease patients.
Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis

Neeta Garg,Elizabeth Jordan Padron,Kottil W Rammohan,Courtney Frances Goodman

DOI: https://doi.org/10.3390/jcm11206139

2022-10-18

Abstract:Bruton's tyrosine kinase (BTK) is an important protein belonging to the tyrosine kinase family that plays a key role in the intracellular signaling and proliferation, migration, and survival of normal and malignant B-lymphocytes and myeloid cells. Understanding the role of BTK in the B-cell signaling pathway has led to the development of BTK inhibitors (BTKi) as effective therapies for malignancies of myeloid origin and exploration as a promising therapeutic option for other cancers. Given its central function in B-cell receptor signaling, inhibition of BTK is an attractive approach for the treatment of a wide variety of autoimmune diseases that involve aberrant B-cell function including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). Here, we review the role of BTK in different cell signaling pathways, the development of BTKi in B-cell malignancies, and their emerging role in the treatment of MS and other autoimmune disorders.
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

Aqu Alu,Hong Lei,Xuejiao Han,Yuquan Wei,Xiawei Wei

DOI: https://doi.org/10.1186/s13045-022-01353-w

2022-10-03

Abstract:Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target for various B cell malignancies and inflammatory diseases. Five small molecule inhibitors have shown remarkable efficacy and have been approved to treat different types of hematological cancers, including ibrutinib, acalabrutinib, zanubrutinib, tirabrutinib, and orelabrutinib. The first-in-class agent, ibrutinib, has created a new era of chemotherapy-free treatment of B cell malignancies. Ibrutinib is so popular and became the fourth top-selling cancer drug worldwide in 2021. To reduce the off-target effects and overcome the acquired resistance of ibrutinib, significant efforts have been made in developing highly selective second- and third-generation BTK inhibitors and various combination approaches. Over the past few years, BTK inhibitors have also been repurposed for the treatment of inflammatory diseases. Promising data have been obtained from preclinical and early-phase clinical studies. In this review, we summarized current progress in applying BTK inhibitors in the treatment of hematological malignancies and inflammatory disorders, highlighting available results from clinical studies.

oncology,hematology
The role of Bruton's tyrosine kinase in the immune system and disease

Charlotte McDonald,Charalampos Xanthopoulos,Efterpi Kostareli

DOI: https://doi.org/10.1111/imm.13416

2021-10-04

Immunology

Abstract:Bruton's Tyrosine kinase (BTK) is a TEC kinase with a multifaceted role in B-cell biology and function, highlighted by its position as a critical component of the B-cell receptor signalling pathway. Due to its role as a therapeutic target in several haematological malignancies including Chronic Lymphocytic Leukaemia, BTK has been gaining tremendous momentum in recent years. Within the immune system, BTK plays a part in numerous pathways and cells beyond B-cells (i.e., T-cells, macrophages). Not surprisingly, BTK has been elucidated to be a driving factor not only in lymphoproliferative disorders but also in autoimmune diseases and response to infection. To extort this role, BTK inhibitors such as Ibrutinib have been developed to target BTK in other diseases. However, due to rising levels of resistance, the urgency to develop new inhibitors with alternative modes of targeting BTK is high. To meet this demand, an expanding list of BTK inhibitors is currently being trialled. In this review, we synopsize recent discoveries regarding BTK and its role within different immune cells and pathways. Additionally, we discuss the broad significance and relevance of BTK for various diseases ranging from the haematology and rheumatology to the COVID-19 pandemic. Overall, BTK signalling and its targetable nature have emerged as immensely important for a wide range of clinical applications. The development of novel, more specific and less toxic BTK inhibitors could be revolutionary for a significant number of diseases with yet unmet treatment needs.

immunology
Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment

Logan Good,Brooke Benner,William E. Carson

DOI: https://doi.org/10.1007/s00262-021-02908-5

2021-04-05

Abstract:Abstract Bruton’s tyrosine kinase (BTK) is a non-receptor kinase belonging to the Tec family of kinases. The role of BTK in B cell receptor signaling is well defined and is known to play a key role in the proliferation and survival of malignant B cells. Moreover, BTK has been found to be expressed in cells of the myeloid lineage. BTK has been shown to contribute to a variety of cellular pathways in myeloid cells including signaling in the NLRP3 inflammasome, receptor activation of nuclear factor-κβ and inflammation, chemokine receptor activation affecting migration, and phagocytosis. Myeloid cells are crucial components of the tumor microenvironment and suppressive myeloid cells contribute to cancer progression, highlighting a potential role for BTK inhibition in the treatment of malignancy. The increased interest in BTK inhibition in cancer has resulted in many preclinical studies that are testing the efficacy of using single-agent BTK inhibitors. Moreover, the ability of tumor cells to develop resistance to single-agent checkpoint inhibitors has resulted in clinical studies utilizing BTK inhibitors in combination with these agents to improve clinical responses. Furthermore, BTK regulates the immune response in microbial and viral infections through B cells and myeloid cells such as monocytes and macrophages. In this review, we describe the role that BTK plays in supporting suppressive myeloid cells, including myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM), while also discussing the anticancer effects of BTK inhibition and briefly describe the role of BTK signaling and BTK inhibition in microbial and viral infections.
Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments

Gita Manzari Tavakoli,Niloufar Yazdanpanah,Nima Rezaei

DOI: https://doi.org/10.1186/s42358-024-00401-y

2024-08-21

Abstract:Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, plays a remarkable role in the transmission and amplification of extracellular signals to intracellular signaling pathways. Various types of cells use the BTK pathway to communicate, including hematopoietic cells particularly B cells and T cells. The BTK pathway plays a role in controlling the proliferation, survival, and functions of B cells as well as other myeloid cells. First, second, and third-generation BTK inhibitors are currently being evaluated for the treatment of immune-mediated diseases in addition to B cell malignancies. In this article, the available evidence on the action mechanisms of BTK inhibitors is reviewed. Then, the most recent data obtained from preclinical studies and ongoing clinical trials for the treatment of autoimmune diseases, such as pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, systemic lupus erythematosus, Sjögren's disease, rheumatoid arthritis, systemic sclerosis, multiple sclerosis, myasthenia gravis, and inflammatory diseases such as psoriasis, chronic spontaneous urticaria, atopic dermatitis, and asthma are discussed. In addition, adverse effects and complications associated with BTK inhibitors as well as factors predisposing patients to BTK inhibitors complications are discussed.
Bruton's Tyrosine Kinase As a Drug Discovery Target.

Zhengying Pan

DOI: https://doi.org/10.1358/dnp.2008.21.7.1255308

2008-01-01

Drug News & Perspectives

Abstract:Bruton's tyrosine kinase (Btk) is an important mediator in multiple signal transduction pathways. Fifteen years of research have revealed a complex role for Btk in hematopoietic cells. These studies suggest that Btk may be a promising target for therapeutic intervention for several complicated diseases. Inhibitors targeting the Btk kinase domain have been developed and show clear beneficial effects in animal models of rheumatoid arthritis, lymphoma and other diseases. Here, an overview of these studies is presented with an emphasis on results stemming from medicinal chemistry research.
Insertional Transposon Mutagenesis in the Xylella fastidiosa Citrus Variegated Chlorosis Strain with Transposome

T. Koide,J. Neto,S. Gomes,M. Marques

DOI: https://doi.org/10.1007/s00284-003-4189-z

IF: 2.343

2004-04-01

Current Microbiology

Abstract:
Further investigations in the methionine malabsorption syndrome.

C. Hooft,D. Carton,J. Snoeck,J. Timmermans,I. Antener,C. Van den hende

1968-08-01

Abstract:
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

Michele D. Stanchina,Skye Montoya,Alexey V. Danilov,Jorge J. Castillo,Alvaro J. Alencar,Julio C. Chavez,Chan Y. Cheah,Carlos Chiattone,Yucai Wang,Meghan Thompson,Paolo Ghia,Justin Taylor,Juan Pablo Alderuccio

DOI: https://doi.org/10.1038/s41571-024-00956-1

IF: 78.8

2024-11-02

Nature Reviews Clinical Oncology

Abstract:The B cell receptor (BCR) signalling pathway has an integral role in the pathogenesis of many B cell malignancies, including chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B cell lymphoma and Waldenström macroglobulinaemia. Bruton tyrosine kinase (BTK) is a key node mediating signal transduction downstream of the BCR. The advent of BTK inhibitors has revolutionized the treatment landscape of B cell malignancies, with these agents often replacing highly intensive and toxic chemoimmunotherapy regimens as the standard of care. In this Review, we discuss the pivotal trials that have led to the approval of various covalent BTK inhibitors, the current treatment indications for these agents and mechanisms of resistance. In addition, we discuss novel BTK-targeted therapies, including covalent, as well as non-covalent, BTK inhibitors, BTK degraders and combination doublet and triplet regimens, to provide insights on the best current treatment paradigms in the frontline setting and at disease relapse.

oncology
New means and challenges in the targeting of BTK

Vindhya Nawaratne,Anya K. Sondhi,Omar Abdel-Wahab,Justin Taylor

DOI: https://doi.org/10.1158/1078-0432.ccr-23-0409

IF: 13.801

2024-04-07

Clinical Cancer Research

Abstract:Bruton's tyrosine kinase (BTK) is central to the survival of malignant and normal B-lymphocytes and has been a crucial therapeutic target of several generations of kinase inhibitors and newly developed degraders. These new means for targeting BTK have added additional agents to the armamentarium for battling cancers dependent on B-cell receptor (BCR) signaling, including chronic lymphocytic leukemia and other non-Hodgkin lymphomas. However, the development of acquired resistance mutations to each of these classes of BTK inhibitors has led to new challenges in targeting BTK as well as novel insights into BCR signaling. The first generation covalent BTK inhibitor ibrutinib is susceptible to mutations affecting the covalent binding site, Cysteine 481 (C481). Newer noncovalent BTK inhibitors, such as pirtobrutinib, overcome C481 mutation-mediated resistance but are susceptible to other kinase domain mutations, particularly at residues Threonine 474 and Leucine 528. Additionally, these novel BTK inhibitor resistance mutations have been shown biochemically and in patients to cause cross-resistance to some covalent BTK inhibitors. Importantly, newer generation covalent BTK inhibitors zanubrutinib and acalabrutinib are susceptible to the same mutations which confer resistance to non-covalent inhibitors. The BTK L528W mutation is of particular interest as it disrupts the kinase activity of BTK, rendering it kinase dead. This observation suggests that BTK may act independently of its kinase activity as a scaffold. Thus, the timely development of BTK degrading proteolysis targeting drugs has allowed for degradation, rather than just enzymatic inhibition, of BTK in B-cell lymphomas and early clinical trials to evaluate BTK degraders are underway.

oncology
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Tingyu Wen,Jinsong Wang,Yuankai Shi,Haili Qian,Peng Liu

DOI: https://doi.org/10.1038/s41375-020-01072-6

2020-10-29

Leukemia

Abstract:Abstract Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies, and it is so popular that gross sales have rapidly grown to more than 230 billion dollars in just 6 years, with annual sales exceeding 80 billion dollars; it also became one of the five top-selling medicines in the world. Numerous clinical trials of BTK inhibitors in cancers were initiated in the last decade, and ~73 trials were intensively announced or updated with extended follow-up data in the most recent 3 years. In this review, we summarized the significant milestones in the preclinical discovery and clinical development of BTK inhibitors to better understand the clinical and commercial potential as well as the directions being taken. Furthermore, it also contributes impactful lessons regarding the discovery and development of other novel therapies.

oncology,hematology
Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.

N. Haginoya,Syozo Kobayashi,S. Komoriya,Y. Hirokawa,Taketoshi Furugori,T. Nagahara

DOI: https://doi.org/10.1002/CHIN.200438168

IF: 2.94

2004-06-07

Bioorganic & Medicinal Chemistry Letters

Abstract:In our investigation of factor Xa inhibitors, a series of 1-(6-chloronaphthalen-2-yl)sulfonyl-4-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carbonyl)piperazines 3a-i were synthesized. In vitro inhibitory activities of the compounds against factor Xa and coagulation are summarized. Among the compounds, 3c and 3d, possessing a carbamoyl or N-methylcarbamoyl moiety, showed potent inhibitory activities when administered orally to rats.
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

Matt Shirley

DOI: https://doi.org/10.1007/s11523-021-00857-8

Abstract:Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase (BTK) inhibitors has led to dramatic improvements in the management of B-cell malignancies. Subsequently, more-highly selective second-generation BTK inhibitors (including acalabrutinib, zanubrutinib, tirabrutinib and orelabrutinib) have been developed, primarily with an aim to reduce off-target toxicities. More recently, third-generation agents including the non-covalent BTK inhibitors pirtobrutinib and nemtabrutinib have entered later-stage clinical development. BTK inhibitors have shown strong activity in a range of B-cell malignancies, including chronic lymphocytic leukaemia/small lymphocytic lymphoma, mantle cell lymphoma, Waldenström's macroglobulinaemia and marginal zone lymphoma. The agents have acceptable tolerability, with adverse events generally being manageable with dosage modification. This review article summarises the evidence supporting the role of BTK inhibitors in the management of B-cell malignancies, including highlighting some differential features between agents.
Burgeoning Data on BTK Inactivating Mutations in Lymphomagenesis and Therapeutic Resistance

Carla Risso,Daniel Tsai,Skye Montoya,Jacob Jahn,Justin Taylor

DOI: https://doi.org/10.18103/mra.v10i10.3182

2022-01-01

Medical Research Archives

Abstract:The B-cell antigen receptor signaling pathway has been a primary focus in the targeted treatment of B-cell malignancies for the past decade. When aberrantly activated, this pathway initiates a cascade of phosphorylation mediated by several tyrosine kinases, with Bruton’s tyrosine kinase (BTK) being essential among them. Multiple generations of covalent and non-covalent BTK inhibitors have revolutionized therapeutic options for several B-cell lymphomas. However, the use of continuous BTK inhibition is limited by development of resistance resulting from acquired point mutations that allow persistent B-cell receptor signaling. Genomic sequencing of patient samples at disease progression has recently led to the discovery of novel resistance mutations in BTK that result in diminished or absent BTK kinase activity (termed kinase-deficient). However, the mechanisms underlying the potential advantage of kinase-deficient BTK mutations are incompletely understood and still under investigation. In this review, we provide a background of the pathway leading to the development of current therapies that target BTK and review the literature describing kinase-deficient BTK mutations. We propose that BTK inactivating mutations provide an advantage to neoplastic B-lymphocytes in patients with BTK inhibitor resistant B-cell malignancies and highlight potential mechanisms through which BTK kinase-deficient mutations could be acting, either due to differential protein conformation or by behaving as a scaffold for other signaling molecules. Due to the novelty of these mutations and their increasing rate of incidence over the last decade, it is imperative to continue studying BTK kinase deficient mutations across B-cell malignancies and to propose alternate therapies that could target them.
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

Alycia Hatashima Mazyar Shadman a Fred Hutchinson Cancer Center,University of Washington,Seattle,WA,USAb Division of Hematology and Oncology,University of Washington,Seattle,WA,USA

DOI: https://doi.org/10.1080/17474086.2024.2391097

2024-08-24

Expert Review of Hematology

Abstract:Introduction Bruton's tyrosine kinaseinhibitors (BTKis) changed the trajectory of upfront and relapsed/refractory chronic lymphocytic leukemia (CLL) treatment. However, BTKis are plagued by a spectrum of toxicities. Zanubrutinib was developed to circumvent challenges with prolonged tolerability by increasing BTK selectivity and maximizing efficacy through pharmacokinetic/pharmacodynamic optimization. However, with the availability of ibrutinib, acalabrutinib, and zanubrutinib, limited data exists to guide sequencing of BTKi therapy in the relapsed/refractory setting.

hematology
A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications

Qi Zhang,Changming Wen,Lijie Zhao,Yatao Wang

DOI: https://doi.org/10.3390/molecules28248037

IF: 4.6

2023-12-12

Molecules

Abstract:Bruton tyrosine kinase (BTK) is an essential enzyme in the signaling pathway of the B-cell receptor (BCR) and is vital for the growth and activation of B-cells. Dysfunction of BTK has been linked to different types of B-cell cancers, autoimmune conditions, and inflammatory ailments. Therefore, focusing on BTK has become a hopeful approach in the field of therapeutics. Small-molecule inhibitors of BTK have been developed to selectively inhibit its activity and disrupt B-cell signaling pathways. These inhibitors bind to the active site of BTK and prevent its phosphorylation, leading to the inhibition of downstream signaling cascades. Regulatory authorities have granted approval to treat B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with multiple small-molecule BTK inhibitors. This review offers a comprehensive analysis of the synthesis and clinical application of conventional small-molecule BTK inhibitors at various clinical stages, as well as presents promising prospects for the advancement of new small-molecule BTK inhibitors.

chemistry, multidisciplinary,biochemistry & molecular biology
Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

Jiakuo Liu,Chengjuan Chen,Dongmei Wang,Jie Zhang,Tiantai Zhang

DOI: https://doi.org/10.1016/j.ejmech.2021.113329

IF: 7.088

2021-05-01

European Journal of Medicinal Chemistry

Abstract:<p>Therapy based on Bruton's tyrosine kinase (BTK) inhibitors one of the major treatment options currently recommended for lymphoma patients. The first generation of BTK inhibitor, Ibrutinib, achieved remarkable progress in the treatment of B-cell malignancies, but still has problems with drug-resistance or off-target induced serious side effects. Therefore, numerous new BTK inhibitors were developed to address this unmet medical need. In parallel, the effect of BTK inhibitors against immune-related diseases has been evaluated in clinical trials. This review summarizes recent progress in the research and development of BTK inhibitors, with a focus on structural characteristics and structure-activity relationships. The structure-refinement process of representative pharmacophores as well as their effects on binding affinity, biological activity and pharmacokinetics profiles were analyzed. The advantages and disadvantages of reversible/irreversible BTK inhibitors and their potential implications were discussed to provide a reference for the rational design and development of novel potent BTK inhibitors.</p>

chemistry, medicinal
Targeting Bruton's tyrosine kinase in B cell malignancies

Rudi W. Hendriks,Saravanan Yuvaraj,Laurens P. Kil

DOI: https://doi.org/10.1038/nrc3702

IF: 78.5

2014-03-24

Nature Reviews Cancer

Abstract:Key PointsBruton's tyrosine kinase (BTK) was originally identified as a non-receptor protein tyrosine kinase that is defective in the inherited immunodeficiency disease X-linked agammaglobulinaemia (XLA).BTK has long been known to be a key component of B cell receptor (BCR) signalling that regulates B cell proliferation and survival.Recently, a small-molecule inhibitor of BTK, called ibrutinib, has shown antitumour activity in patients with various B cell malignancies.The antitumour activity of BTK inhibition is not solely dependent on the role of BTK in BCR signalling.BTK inhibition also targets Toll-like receptor (TLR) signalling, B cell adhesion and migration, as well as cells in the tumour microenvironment.Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukaemia and mantle cell lymphoma leads to the effective expulsion of malignant B cells out of their nursing microenvironment.For many different B cell malignancies, treatment with BTK inhibitors is expected to be more effective and have fewer toxic effects than currently used therapies.

oncology
Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies

Andres Bravo-Gonzalez,Maryam Alasfour,Deborah Soong,Jose Noy,Georgios Pongas

DOI: https://doi.org/10.3390/cancers16203434

2024-10-11

Cancers

Abstract:B-cell lymphoid malignancies are a heterogeneous group of hematologic cancers, where Bruton's tyrosine kinase (BTK) inhibitors have received FDA approval for several subtypes. The first-in-class covalent BTK inhibitor, Ibrutinib, binds to the C481 amino acid residue to block the BTK enzyme and prevent the downstream signaling. Resistance to covalent BTK inhibitors (BTKi) can occur through mutations at the BTK binding site (C481S) but also other BTK sites and the phospholipase C gamma 2 (PLCγ2) resulting in downstream signaling. To bypass the C481S mutation, non-covalent BTKi, such as Pirtobrutinib, were developed and are active against both wild-type and the C481S mutation. In this review, we discuss the molecular and genetic mechanisms which contribute to acquisition of resistance to covalent and non-covalent BTKi. In addition, we discuss the new emerging class of BTK degraders, which utilize the evolution of proteolysis-targeting chimeras (PROTACs) to degrade the BTK protein and constitute an important avenue of overcoming resistance. The moving landscape of resistance to BTKi and the development of new therapeutic strategies highlight the ongoing advances being made towards the pursuit of a cure for B-cell lymphoid malignancies.

oncology

Biologic response-modifying agents: What is an appropriate phase I–II strategy?

Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

The role of Bruton's tyrosine kinase in the immune system and disease

Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment

Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments

Bruton's Tyrosine Kinase As a Drug Discovery Target.

Insertional Transposon Mutagenesis in the Xylella fastidiosa Citrus Variegated Chlorosis Strain with Transposome

Further investigations in the methionine malabsorption syndrome.

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

New means and challenges in the targeting of BTK

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

Burgeoning Data on BTK Inactivating Mutations in Lymphomagenesis and Therapeutic Resistance

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia

A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications

Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

Targeting Bruton's tyrosine kinase in B cell malignancies

Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies